Abstracts Archive - Page 1431 of 2425 - ACR Meeting Abstracts

Abstract Number: 196 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Xiaohong Yan³, Jeffrey N. Miner^3,4, Liz Hicks³, Shakti Valdez³ and Martha Hernandez-Illas⁵, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ⁵QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 197 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Shakti Valdez³, Sha Liu³, Xiaohong Yan³, Liz Hicks³ and Martha Hernandez-Illas⁴, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 198 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout and Moderate Renal Impairment
Lhanoo Gunawardhana¹, Michael A. Becker², Andrew Whelton³, Barbara Hunt¹, Majin Castillo¹, Xinxin Dong¹ and Kenneth Saag⁴, ¹Takeda Pharmaceuticals International, Deerfield, IL, ²Medicine, University of Chicago, Chicago, IL, ³Johns Hopkins University, Hunt Valley, MD, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Data generated by Phase 1 and 2 studies suggest that the extended-release (XR) formulation of febuxostat (FBX) may provide equal or better reduction in…
Abstract Number: 199 • 2016 ACR/ARHP Annual Meeting
A Phase 3 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout
Kenneth Saag¹, Michael A. Becker², Andrew Whelton³, Barbara Hunt⁴, Majin Castillo⁴, Krisztina Kisfalvi⁴ and Lhanoo Gunawardhana⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medicine, University of Chicago, Chicago, IL, ³Johns Hopkins University, Hunt Valley, MD, ⁴Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: Data generated by Phase 1 and 2 studies suggest that the extended-release (XR) formulation of febuxostat (FBX) may provide equal or better reduction in…
Abstract Number: 200 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Benzbromarone in Gout in Aotearoa New Zealand
Lisa K. Stamp¹, Janine Haslett¹, Christopher Frampton¹, Doug White², David Gardner³, Simon Stebbings⁴, Guy Taylor⁵, Rebecca Grainger⁶, Rajesh Kumar⁷, Sunil Kumar⁸, Tracey Kain⁹, David Porter¹⁰, Michael Corkill¹¹, Angela Cathro¹², Scott Metcalfe¹², John Wyeth¹² and Nicola Dalbeth¹³, ¹University of Otago, Christchurch, New Zealand, ²Waikato Hospital, Hamilton, New Zealand, ³Hawkes Bay DHB, Napier, New Zealand, ⁴Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, ⁵Whanganui Hospital, Whanganui, New Zealand, ⁶Wellington Regional Rheumatology Unit, Hutt Valley District Health Board, Lower Hutt, New Zealand, ⁷Taranaki Hospital, New Plymouth, New Zealand, ⁸Middlemore Hospital, Auckland, New Zealand, ⁹Tauranga Hospital, Tauranga Hospital, Tauranga, New Zealand, ¹⁰Porter Rheumatology Ltd, The Collingwood Centre, Nelson, New Zealand, ¹¹North Shore Hospital, Auckland, New Zealand, ¹²Pharmaceutical Management Agency, Wellington, New Zealand, ¹³Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Benzbromarone is a potent uricosuric, but is not widely available due to concerns about hepatotoxicity. In Aotearoa New Zealand benzbromarone has been available since…
Abstract Number: 201 • 2016 ACR/ARHP Annual Meeting
Allopurinol Reduces the Risk of Myocardial Infarction (MI) in the Elderly: A Study of Medicare Claims
Jasvinder A. Singh¹ and Shaohua Yu², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess whether allopurinol use reduces the risk of myocardial infarction (MI) in the elderly. Methods: We used the 2006-2012 5% random sample of…
Abstract Number: 202 • 2016 ACR/ARHP Annual Meeting
Allopurinol Use and the Risk of Ventricular Tachycardia in the US Elderly: A Study of Medicare Claims Data
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: To assess whether allopurinol use reduces the risk of ventricular tachycardia in the elderly. Methods: We used the 2006-2012 5% random sample of Medicare…
Abstract Number: 203 • 2016 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Brian W Coburn^1,2, Kaleb Michaud³, Debra A Bergman² and Ted R Mikuls^4,5, ¹Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Allopurinol Dose Escalation and Mortality among Patients with Gout: A National Propensity-Matched Cohort Study Background/Purpose: Numerous epidemiologic studies show that hyperuricemia and gout are associated…
Abstract Number: 204 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate lowering therapy. Many patients on allopurinol fail to achieve target serum urate (SU), in part due to…
Abstract Number: 205 • 2016 ACR/ARHP Annual Meeting
Serum Uric Acid Lowering Treatment Appears Unnecessary during Hemodialysis
Raquel Soriano¹, Mariano Andrés¹, Eloy Oliveira², Celia Trigo², Eliseo Pascual³ and María Dolores Arenas⁴, ¹Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ²Servicio de Análisis Clínicos, Hospital General Universitario de Alicante, Alicante, Spain, ³Departamento de Medicina Clínica, Emeritus Professor, Universidad Miguel Hernández, Alicante, Spain, ⁴Unidad de Nefrología, Hospital Vithas Perpetuo Socorro, Alicante, Spain
Background/Purpose: Gout patients often suffer from renal disease, some ultimately developing end-stage renal disease (ESRD) and requiring hemodialysis (HD) replacement therapy. Though some reports suggested…
Abstract Number: 206 • 2016 ACR/ARHP Annual Meeting
Renal Safety of Lesinurad: A Pooled Analysis of Phase III and Extension Studies
Robert Terkeltaub¹, Raymond Malamet², Kathleen Bos², Jingyi Li², David Goldfarb³, Michael Pillinger⁴, Diana Jalal⁵, Jia Hu⁶ and Kenneth Saag⁷, ¹Rheumatology, VA Medical Center, San Diego, CA, ²AstraZeneca Pharmaceuticals, Wilmington, DE, ³New York University School of Medicine, New York, NY, USA, New York, NY, ⁴Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁵University of Colorado Anschutz Medical Center, Aurora, CO, USA, Aurora, CO, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor approved in the United States and European Union at 200 mg daily dose in combination with…
Abstract Number: 207 • 2016 ACR/ARHP Annual Meeting
Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout
Michael A. Becker¹, Robert T. Keenan², Puja Khanna³, Raymond Malamet⁴, Kathleen Bos⁴, Jingyi Li⁴, Jia Hu⁵ and William White⁶, ¹University of Chicago, Chicago, IL, ²Rheumatology, Duke University, Durham, NC, ³Rheumatology, University of Michigan, Ann Arbor, MI, ⁴AstraZeneca Pharmaceuticals, Wilmington, DE, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶University of Connecticut School of Medicine, Farmington, CT
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor recently approved at 200 mg daily in combination with a xanthine oxidase inhibitor (XOI) for treatment…
Abstract Number: 208 • 2016 ACR/ARHP Annual Meeting
Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Kenneth Saag¹, Michael A. Becker², Chris Storgard³, Maple Fung³, Jia Hu³ and Thomas Bardin⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago, Chicago, IL, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Hôpital Lariboisière, Paris, France
Background/Purpose: Two replicate, randomized, core Phase III trials (CLEAR 1 & 2) reported significantly more subjects treated with lesinurad 200 mg (LESU200) or 400 mg…
Abstract Number: 209 • 2016 ACR/ARHP Annual Meeting
Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout
Thomas Bardin¹, Nicola Dalbeth², Robert Terkeltaub³, Chris Storgard⁴, Maple Fung⁴, Jia Hu⁴ and Fernando Perez-Ruiz⁵, ¹Hôpital Lariboisière, Paris, France, ²University of Auckland, Auckland, New Zealand, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Hospital de Cruces and Biocruces Health Research Institute, Vizcaya, Spain
Background/Purpose: Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad 200 mg (LESU200) or 400 mg (LESU400), combined with…
Abstract Number: 210 • 2016 ACR/ARHP Annual Meeting
Skin Events with Febuxostat in Gout Patients and Previous Skin Reactions to Allopurinol. a Retrospective Review
Neus Quilis¹, Mariano Andrés^1,2, Carlos Muñoz³, Paloma Vela^1,2 and Eliseo Pascual⁴, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ³Sección de Inmunología, Hospital General Universitario de Alicante, Alicante, Spain, ⁴Departamento de Medicina Clínica, Emeritus Professor, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Allopurinol is the most used urate-lowering agent for patients with gout, but around 10% of patients show intolerance to this drug, often at skin,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].